The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Pfizer Renames Japan Subsidiaries as Mylan Deal Set to Close Soon; Upjohn Biz Now Separate
With the closing of its generic merger with Mylan imminent, Pfizer has changed the names of two of its Japanese subsidiaries, effectively separating its Upjohn off-patent drug business from innovative medicines operations in the country, it has been learned. In…
To read the full story
Related Article
- Viatris Japan to Go After Drugs in All Phases of Life Cycle, Group Consolidation by Year-End: Chief
September 26, 2023
- Viatris Launches New Headquarters in Tokyo
April 6, 2021
- As Pfizer/Mylan’s Generics Merger Closed, 4 Viatris Group Firms to Operate Together in Japan
November 18, 2020
- In Japan Too, Pfizer and Mylan Prepping for Pending Viatris Integration
February 12, 2020
BUSINESS
- Pfizer Releases Nurtec Migraine Drug in Japan
December 17, 2025
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Eisai Flags Nitrosamine Found in Merislon, Says Supply to Continue
December 16, 2025
- Mochida to Bring in Morning Sickness Drug from Canada’s Duchesnay
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…